• Skip to main content
  • Skip to footer
Eco Friendly CBD OIL

Eco Friendly CBD OIL

The Best Eco Friendly CBD Oil

  • Home
  • CBD Health
  • Cannabis News
  • Contact

CBD OIL

How Far Away Is Adult Use Cannabis Reform On The Global Calendar?

November 30, 2020 by CBD OIL

There is an ineffable logic to the pace of reform these days. Nowhere is that clearer in both the success of voter reform measures in the United States (along with timelines for implementation baked into the language of the same) and developments internationally. No matter that New Zealand decided to take a recent punt on the issue, there are other forces moving elsewhere that have the potential to be far more consequential – and in the short term.

Israel Announced Its Intent To Create A Recreational Market in 2021

israel flagThere is little news anywhere as consequential as that of the oldest medical market finally succumbing to the inevitable. Namely, Israel has announced that it will allow an adult use market to begin operations probably by the third quarter of 2021. That said, don’t hold anyone to a deadline in the days of COVID-19, which will just as surely have not passed by then.

However, this development means that the entire conversation has moved up a notch – because the Israelis have so much research on the plant at this point.

For this reason, the tiny country is likely to have an outsized impact on the entire discussion – along with conveniently timed medical exports to the world.

Luxembourg Will Initiate Its Recreational Market Shortly Thereafter

It is likely not insignificant that the Israelis announced their intent to begin an adult use market just ahead of the long-announced Luxembourg flip – now on the agenda of the Green Party domestically for several years.

The strategic location of Luxembourg in both the European market as well as the much larger financial one now interested in the vertical cannot be understated. Indeed, the country has already played an outsized role in the development of the medical market here due to the contretemps over the clearing of stock trades in the German market as of 2018.

The double whammy of good news from both markets will also create a buzz internationally that is sure to drive other conversations forward – even if it is to study how both countries approach the issue. And, more to a point, how they differ from Canada, including regulation of their equity markets.

Combined with a more regulated market in Holland and presumably continued “experimentation” in Denmark, and by the end of next year, adult use reform will have hit the continent and in no small way.

Does This Mean The Sudden Potential of Adult Use Everywhere?

As 2020 has shown, in spades, just about anything can and frequently does happen. However, do not expect many more countries to move into the recreational column for the next several years.

Whatever the UN does or does not do about cannabis at the next meeting of the WHO, cannabis the plant remains a Schedule I drug internationally. This means that, for example, import and export of the same across borders, even in Europe, is likely to be problematic and for some time to come – let alone its international travel across say, the Atlantic.

Further from the law enforcement and financial security (namely money laundering) perspective, there are big issues that have to be dealt with finally, internationally, that so far have not – and under the guise of “medical reform.”

For that reason, in other words, do not expect Germany, much less France or even the UK to suddenly switch gears. And remember that both Luxembourg and Israel are small countries.

Bottom line? Adult use reform is here to stay, and will increasingly show up on the map. But the more “blanket” reform, still driving the entire discussion, is broadly, and globally, medical.

Filed Under: Cannabis News

Virginia Medical Cannabis Coalition Hopes State Builds on Existing Medical Program to Launch Adult-Use Market: Legalization Watch

November 30, 2020 by CBD OIL

Earlier this month, the California Bureau of Cannabis Control (BCC) announced the recipients of public university grant funding that will allow universities across the state to research the legal cannabis system and its impacts, and researchers are eager to launch their wide-ranging studies.

More than 100 universities applied for grants of up to $2 million to fund research proposals that had to fall within one of several specified categories, including public health, criminal justice and public safety, and economic and environmental impacts of the legal cannabis industry.

The BCC ultimately awarded nearly $30 million in funding to UC San Francisco, UC Santa Barbara, CSU Dominguez Hills, UC Berkeley, UC Los Angeles, UC Irvine, UC San Diego, UC Davis and CSU Humboldt for their specified research proposals.

UCLA received seven grants totaling $6.4 million to fund studies that will be conducted through the Semel Institute/Department of Psychiatry, Integrative Substance Abuse Programs (ISAP), Center for Health Services and Society, Department of Family Medicine, Division of Pulmonary and Critical Care, Division of Infectious Disease, Luskin School of Public Policy and the UCLA Labor Center.

Funded studies will focus on the impact of Prop. 64 on maladaptive cannabis use and treatment for cannabis use disorder, as well as the toxicity of inhaled and second-hand cannabis smoke, the neurobiological and behavioral impact of cannabis marketing, employment conditions in California’s cannabis industry, a demographic analysis of the licensed cannabis industry and cannabis consumers, and an assessment of the feasibility and consequences of implementing a cannabis potency tax.

“The funded grants exemplify the breadth of cannabis research at UCLA,” Ziva Cooper, Ph.D and director of the UCLA Cannabis Research Initiative, told Cannabis Business Times and Cannabis Dispensary in an emailed statement.

UC Davis received five grants totaling $3.1 million to fund studies on the impact of cannabis use in early psychosis, an assessment of the demographics of the licensed cannabis industry, the economic impacts of the industry on the private and public sectors in California, the environmental impacts of licensed and unlicensed cannabis cultivation in the state, and a study on California’s cannabis workers.

“We have a Cannabis and Hemp Research Center at UC Davis that fosters scientific research, as well as a dissemination of knowledge related to the many scientific disciplines associated with cannabis and hemp, and that includes agricultural science, environmental science, pharmacology and clinical medicine,” Cam Carter, co-director of the research center, told CBT and CD, adding that the grant funding will support research across all of these areas. “The area that our research is focused on is the effects of cannabis use on the brain, brain function and brain health in young people with serious mental illness. We want to understand the complexities, particularly adverse effects and clinical outcomes, as well as potential therapeutic effects associated with cannabis use in high-risk, young populations.”

One group of researchers will focus specifically on economic issues, Carter said, particularly economic development and equity in California’s legal cannabis industry. Much of that research will rely on information from public records, as well as interviews with various participants in the industry and an analysis of policy related to economic development and equity.

Other studies will focus on the occupational health for workers who participate in California’s legal cannabis industry, as well as health-related research involving cannabis consumers who are receiving mental care, Carter added.

“That research will involve clinical interviews and evaluations, metabolic and inflammatory markers, and brain imaging studies, looking at the function and structure of the brain in those young people,” he said.

The goal of the research funding program, which is supported by state tax dollars, is to provide a better understanding of the impact of cannabis legalization on California’s economy, environment and public health, Carter said. He expects the results of UC Davis’ research to be published in scientific journals and white papers, and hopes that the research will have many positive outcomes.

“We would like to see an industry that is contributing positively to the economy, doing that in a way that’s equitable, that’s not in any way harmful to the health of people who are actually participating in the industry,” Carter said. “And we’d definitely like to have a better understanding on the impact of the industry and cannabis use in general on high-risk populations, such as those who are young, whose brains are still developing, or who have mental health problems.”

Filed Under: Cannabis News

Are We Getting Closer to Federal Cannabis Legalization and Greater Clarity on CBD?

November 28, 2020 by CBD OIL

After election day, cannabis stocks jumped to around 30% to 40%. Much of this economic excitement was thanks to the fact that four states legalized adult-use cannabis consumption: Arizona, New Jersey, Montana, and South Dakota. With that, about one-third of Americans now have the legal right to consume cannabis.

Unfortunately, we aren’t certain these efforts are going to open up opportunities for federal legalization. At least, not in the near future.

Currently, a bill is circling Capitol Hill known as the Marijuana Opportunity Reinvestment and Expungement (MORE) Act. If passed, it would make cannabis a decriminalized substance and remove it from Schedule I. Not to mention, it would allow those with previous cannabis charges to begin the process of expungement.

While this wouldn’t legalize cannabis, it would certainly pave the way for legalization.

The House of Representatives is expected to vote on the MORE Act in December and, given their political leanings, there’s a healthy chance it will pass. From there, it will be taken to the Senate where there’s just as healthy a chance it won’t pass.

This past election season, Republicans won the majority in the Senate again, many of whom are against cannabis legalization. Being the US legal process and the current seats held down in the Senate, it’s extremely unlikely a federal cannabis legalization bill will pass within the next two years. But we shouldn’t give up hope.

Recent polls have revealed that nearly two-thirds of Americans think legalizing cannabis is a good idea. And with more and more Americans opening up to the idea, it’s likely the politicians will eventually follow.

For if they want to be voted in again, they’re going to have to listen to what we’re asking for.

In addition to the legal status of cannabis as a whole, the cannabidiol (CBD) industry has also been waiting on guidance from the Food and Drug Administration (FDA), as well as additional feedback from the Drug Enforcement Agency (DEA). Without knowing if CBD will be treated as a supplement or how evolving policies will impact hemp extraction and processing, the industry stands in limbo, lacking standardizations across the board, most importantly of all, lacking testing standards.

With all this said, it’s likely we’re going to see more states legalize medical and adult-use programs within the next few years and, hopefully, greater advances in CBD policy.

Image Credit: Louis Velazquez

Image Source: https://unsplash.com/photos/XWW746i6WoM

Filed Under: CBD Health

Scams Plague CBD Industry – CBD Health and Wellness

November 28, 2020 by CBD OIL

The cannabidiol (CBD) industry is often called the “Wild West” due to a lack of standard regulations. It’s also thick with scammers trying to get rich quick who no nothing about the plant. According to the Food and Drug Administration (FDA), further regulations will be implemented soon, but until that happens, unscrupulous companies can take advantage of the public’s interest in CBD.

Be Wary of Swindlers

There’s more than one way to be fooled by a CBD company. One very important issue is the  actual CBD content within products. In 2019, the FDA looked at popular CBD products and tested the accuracy of their labels. Among the products they examined that purported to contain a specific amount of CBD, more than half contained “less than 80% of the CBD amount indicated.” You may be paying top-dollar for “CBD” that’s little more than plain oil. Not to mention that people who need CBD for medical conditions will not get the relief they need.

You can also lose a lot of money if you trust the wrong CBD company. A standard scheme used by other industrues is to lure customers in with a free trial offer. They’ll send you a CBD sample, and all you have to do is pay shipping and handling fees. Many people miss the fine print that says they’ll be on the hook for a much heftier charge when their free trial ends. Or, in some cases, the company commits blatant fraud and charges the customer without informing them or giving them a way to cancel the payment.

A recent example is from a company that used images of a celebrity to instill trust in people and convince them to hand over their credit card information in exchange for a few CBD products. After charging a nominal shipping fee, the company then hit customers with multiple charges totaling more than £160.

Another important consideration is to look closely at the claims companies are making. While some CBD blends may include other substances like herbs or serotonin to help promote sleep, do not buy products claiming to “cure” any disease. Medical claims cannot be made at this time for CBD products, and many companies have received Warning Letters from the FDA due to this issue.

The Bottom Line

When you’re buying CBD, stick with well-known, reputable companies. All companies should publish independent testing data showing the quality of their products. Find a company that you feel comfortable with and don’t be afraid to ask questions.

Ask your doctor and dispensary if they recommend any companies or products. And take a look at our product reviews, which do a deep dive on different companies, highlights their pros and cons, and provides an in-depth look at what they offer.

Always be a vigilant consumer, ask questions, and be wary of any wellness products you buy.

Image Credit: Mediamodifier

Image Source: https://pixabay.com/photos/ecommerce-selling-online-2140603/

Filed Under: CBD Health

Maine’s First Month of Adult-Use Sales Reach $1.4 Million, Georgia Begins Accepting Medical Cannabis Cultivation Licenses: Week in Review

November 28, 2020 by CBD OIL

Earlier this month, the California Bureau of Cannabis Control (BCC) announced the recipients of public university grant funding that will allow universities across the state to research the legal cannabis system and its impacts, and researchers are eager to launch their wide-ranging studies.

More than 100 universities applied for grants of up to $2 million to fund research proposals that had to fall within one of several specified categories, including public health, criminal justice and public safety, and economic and environmental impacts of the legal cannabis industry.

The BCC ultimately awarded nearly $30 million in funding to UC San Francisco, UC Santa Barbara, CSU Dominguez Hills, UC Berkeley, UC Los Angeles, UC Irvine, UC San Diego, UC Davis and CSU Humboldt for their specified research proposals.

UCLA received seven grants totaling $6.4 million to fund studies that will be conducted through the Semel Institute/Department of Psychiatry, Integrative Substance Abuse Programs (ISAP), Center for Health Services and Society, Department of Family Medicine, Division of Pulmonary and Critical Care, Division of Infectious Disease, Luskin School of Public Policy and the UCLA Labor Center.

Funded studies will focus on the impact of Prop. 64 on maladaptive cannabis use and treatment for cannabis use disorder, as well as the toxicity of inhaled and second-hand cannabis smoke, the neurobiological and behavioral impact of cannabis marketing, employment conditions in California’s cannabis industry, a demographic analysis of the licensed cannabis industry and cannabis consumers, and an assessment of the feasibility and consequences of implementing a cannabis potency tax.

“The funded grants exemplify the breadth of cannabis research at UCLA,” Ziva Cooper, Ph.D and director of the UCLA Cannabis Research Initiative, told Cannabis Business Times and Cannabis Dispensary in an emailed statement.

UC Davis received five grants totaling $3.1 million to fund studies on the impact of cannabis use in early psychosis, an assessment of the demographics of the licensed cannabis industry, the economic impacts of the industry on the private and public sectors in California, the environmental impacts of licensed and unlicensed cannabis cultivation in the state, and a study on California’s cannabis workers.

“We have a Cannabis and Hemp Research Center at UC Davis that fosters scientific research, as well as a dissemination of knowledge related to the many scientific disciplines associated with cannabis and hemp, and that includes agricultural science, environmental science, pharmacology and clinical medicine,” Cam Carter, co-director of the research center, told CBT and CD, adding that the grant funding will support research across all of these areas. “The area that our research is focused on is the effects of cannabis use on the brain, brain function and brain health in young people with serious mental illness. We want to understand the complexities, particularly adverse effects and clinical outcomes, as well as potential therapeutic effects associated with cannabis use in high-risk, young populations.”

One group of researchers will focus specifically on economic issues, Carter said, particularly economic development and equity in California’s legal cannabis industry. Much of that research will rely on information from public records, as well as interviews with various participants in the industry and an analysis of policy related to economic development and equity.

Other studies will focus on the occupational health for workers who participate in California’s legal cannabis industry, as well as health-related research involving cannabis consumers who are receiving mental care, Carter added.

“That research will involve clinical interviews and evaluations, metabolic and inflammatory markers, and brain imaging studies, looking at the function and structure of the brain in those young people,” he said.

The goal of the research funding program, which is supported by state tax dollars, is to provide a better understanding of the impact of cannabis legalization on California’s economy, environment and public health, Carter said. He expects the results of UC Davis’ research to be published in scientific journals and white papers, and hopes that the research will have many positive outcomes.

“We would like to see an industry that is contributing positively to the economy, doing that in a way that’s equitable, that’s not in any way harmful to the health of people who are actually participating in the industry,” Carter said. “And we’d definitely like to have a better understanding on the impact of the industry and cannabis use in general on high-risk populations, such as those who are young, whose brains are still developing, or who have mental health problems.”

Filed Under: Cannabis News

DEA Interim Final Rule Poses a “Potential Threat” to the Hemp Industry

November 28, 2020 by CBD OIL

The US Drug Enforcement Agency (DEA) has released an Interim Final Rule to align its current classification of cannabis within the Controlled Substances Act (CSA) with the recently passed 2018 Farm Bill. This bill rubber-stamped industrial hemp production, removing Cannabis sativa L. containing a delta-9-tetrahydrocannabinol (THC) level of less than 0.3% from the auspices of the CSA.

In the new interim final rule, the DEA will designate all hemp products with THC levels greater than 0.3% as illegal and a violation of CSA statutes. This legal change poses a grave risk for owner/operators within the hemp supply chain, from growers to processors.

Although “hot hemp,” i.e., hemp above the THC threshold, is a well-known issue amongst farmers, cannabidiol (CBD) producers, and regulatory officials, the DEA ruling effectively criminalizes the problem instead of solving it.

“In order to meet the [Agriculture Improvement Act]’s definition of hemp, and thus qualify for the exception in the definition of marihuana, a cannabis-derived product must itself contain 0.3% or less 9-THC on a dry weight basis,” described the ruling.

We asked Brandon J. Beatty, CEO and founder of Bluebird Botanicals, what he thought the implications of the ruling on the CBD and hemp industries could be.

“This language does pose a potential threat to the CBD industry. The language stipulates that once a cannabis product at any stage surpasses 0.3%, it’s classified as ‘marijuana’ and therefore a schedule I drug under the purview of the DEA,” Beatty said.

He further added, “This is problematic for the CBD and hemp industry because there’s usually one significant step in the CBD manufacturing process when THC content will exceed 0.3%,” which Congress had accounted for in the 2018 Farm Bill but the DEA has seemingly ignored.

This poses a significant risk for hemp extractors according to Beatty, since “hundreds of millions of dollars’ worth of extraction equipment in this country would be obsolete, and most extraction companies wouldn’t be able to pivot and would go out of business,” because hemp is known to the 0.3% threshold at multiple points in the refinement process.

In all, the recent DEA rules on hemp and acceptable limits of THC content raises a bevy of pertinent questions. For one, it is unclear how the changes will affect the fledgling delta-8 THC industry, which has just begun to explore the potential benefits of this cannabinoid in hemp. It also remains to be seen how this will solve the problem of “hot hemp,” an ongoing issue in hemp growing states across the US.

Of course, there is also the possibility that Congress may act on the DEA’s newest overreach into the hemp industry, establishing a clear legal precedent, which could curtail further encroachments by the DEA.

The DEA guidance is open to public comments until October 20.

 Image Credit: Julia Teichmann

Image Source: https://pixabay.com/users/cbd-infos-com-13065354/

Filed Under: CBD Health

International Task Force Puts Forth Recommendations on Medicinal Cannabis Use

November 28, 2020 by CBD OIL

For decades, opioids have been the most widely used medications for the treatment of pain. However, these drugs have exacted a heavy toll on society. For this reason, the health sector is in desperate need of other medications that can effectively treat pain.

Many researchers and physicians know that cannabidiol (CBD) and other cannabinoids may offer a solution to pain without the addictive nature of opioids. However, clinical trials into cannabis as a pain reliever is lacking (despite plenty of evidence from observational and prospective studies), and there have been little guidance for medical professionals in prescribing it for patients.

To address this problem, an international task force, known as the Global Task Force on Dosing and Administration of Medical Cannabis, has come up with protocols for the use of cannabis for pain relief. Arun Bhaskar, MD, of Imperial College Healthcare NHS Trust Pain Management Centre in London, led the panel of 20 physicians. The guidance was presented during PAINWeek, a live virtual conference held September 11-13, 2020.

“We as a task force believe it’s extremely important to bring [medical cannabis] to patients,” said Dr. Bell. “Our main focus was to provide directions to clinicians.”

The first protocol involves treating patients using a routine scale. It dictates beginning with 5mg of cannabidiol (CBD) two times each day. This dosage is to increase until pain relief is achieved. If pain relief is not achieved by 40mg a day of CBD, then tetrahydrocannabinol (THC) can be added to the mix in dosages starting at 2.5mg daily, which would be capped at 40mg daily.

For the frailest of patients who are elderly and/or have severe co-morbidities, THC is to be issued conservatively. The task force recommends beginning with 1mg per day and increasing it slowly if needed.

Finally, the task force addresses patients in severe pain and those with an extensive history of cannabis consumption. Patients in these categories can be given cannabis under a rapid protocol, which allows doctors to administer equal doses of CBD and THC containing between 2.5 and 5 mg of each cannabinoid once to two times per day.

Members of the task force favor starting with CBD because many have seen its sole use for pain as effective. Additionally, they recommended that all medicinal cannabis be administered orally for ease of use.

The task force advised that pregnant women and those who breastfeed should abstain from medicinal cannabis, as well as those with psychotic disorders.

Members of the task force included physicians from North America, Brazil, Africa, and Europe. Some had extensive experience using medicinal cannabis on their patients in a variety of fields of medicine, including, oncology, primary care, and pediatrics.

In their poster, the group emphasized: “Tailoring medical cannabis treatment to the individual is a critical component of successful treatment.”

As always, speak to your doctor before initiating use of any therapy, including cannabinoids.

Image Credit: Karolina Grabowska

Image Source: https://www.pexels.com/photo/crop-unrecognizable-woman-showing-chiropractor-painful-spot-on-back-4506109/

Filed Under: CBD Health

MACE Media Group Magazines Are Now Digital-only & Free to All Readers

November 28, 2020 by CBD OIL

Pismo Beach, CA, September 22, 2020 — MACE Media Group, one of the nation’s largest diversified media and information companies in the cannabis space, announced today that all of their magazines will now be free and digital-only.

The COVID-19 era has significantly altered the way readers prefer to consume content. After talking with different stakeholders, MACE Media decided that digital-only delivery would provide the safest method of readership due to health and sanitation issues.

The decision to go digital-only is accompanied by zero cost to readers, opening up a new portfolio of rich content that will be available to all. As of today, there will be no barriers to accessing any issues of MACE Media magazines, which include Terpenes & Testing, Extraction Magazine, CBD Health & Wellness, and Hemp Farmer. Print copies of the magazines will be available in limited supply upon direct request.

This decision is permanent for all magazines under the company’s banner, except for The Journal of Cannabinoid Medicine, which will be printed twice a year at a subscription rate.

MACE Media Group CEO Celeste Miranda is greatly looking forward to sharing the company’s diversified, in-depth content with current and future readers within the cannabis industry.

“We’ve all faced new challenges within the past year, and the team at MACE has quickly adapted to this new world,” she said. “The decision to go digital-only made the most sense to us. In addition to furthering the reach of our content, the cost savings allowed us to remove subscription fees and make everything open access.”

For readers who are interested in accessing current and past issues of each magazine, there is an option to view these on desktop, as well as on apps for each magazine through Google Play or iTunes. The company is also working on building a dedicated app allowing access to all publications in one place.

To access magazine content, please visit the following URLs:

Terpenes & Testing: https://terpenesandtesting.com/subscription/

Extraction Magazine: https://extractionmagazine.com/subscribe/

CBD Health & Wellness: https://cbdhealthandwellness.net/subscription/

Hemp Farmer: https://hempfarmermagazine.net/subscribe/

You can also sign up for each magazine’s newsletter, which delivers fresh content from curated blogs to your Inbox every week.

About MACE Media Group

MACE Media Group publishes niche cannabis industry trade publications. Its premiere title, Terpenes and Testing Magazine, was the first industry trade publication devoted to cannabis science. Its newer publications, CBD Health & Wellness Magazine, Extraction Magazine, and Hemp Farmer, revolve around the growing cannabinoid industry to provide news on trending applications, medical research, and updates with laws and regulations.

MACE also produces many trade events that attract dozens of cannabis and mainstream media journalists. Currently, MACE Media Group is producing a tour of CBD expos bringing together thousands of industry influencers, forming the most comprehensive CBD event in the United States.

Find out more at MACE Media Group or email info@macemediagroup.com

Filed Under: CBD Health

Dr. Dabber® – CBD Health and Wellness

November 27, 2020 by CBD OIL

Who they are: Dr. Dabber has been around since 2013. The company was born from “two guys with a vision, picking and packing orders out of a garage in Florida.” Orders skyrocketed. They moved to Vegas and released the first electric dab rig. Dr. Dabber even trademarked the term “e-rig” but decided to let it go.

Since then, Dr. Dabber has developed several innovations, including induction heating (stay tuned). It’s fair to say the company walks the talk.

Why they’re unique: Dr. Dabber has pushed vaporizer tech and consumer experience to new levels. Striving to minimize health risks and maximize flavor, the company continues to deliver award-winning devices.

What products they have: Vaporizers of varying sizes and types; loads of attachments/accessories, tools, and parts; CBD vape carts. There’s also branded, limited edition playing cards if you’re feelin’ lucky.

The CBD carts are free from additives (like propylene glycol) and instead include terpene blends. Third-party lab reports are a QR scan or link click away.

The newest ticket item is the Stella, a vape pen that heats wax or oil with three temperature settings ranging from 460º to 775º F. The Temperature Coefficient Resistance (TCR) heating element is designed to better control temperature. This means no burnt taste and longer battery life. Another cool feature is the floating vaporization chamber, which keeps the heat in the vape and off your hands.

Perhaps the most popular product is the Switch. The main draw here is induction heating (patent-pending). Take a look at the numbers: 4 seconds to heat. Twenty-five temperature settings ranging from 300º to 800º F. One hundred-and-fifty puffs per charge and 60 minutes to recharge. That said, it’s a desktop vape at 13 inches tall. Though versatile, some users feel the Switch does not work as well for flower.

Attachments for the Switch include the Hive Ball, with a “large water reservoir,” and the Snowflake Recycler, with an “intricate percolator design.”

Aaron G left this comment on the Better Business Bureau®:

“Great products that don’t break the bank and the customer service team at Dr. Dabber are second to none. I’ve had an issue or two with orders but all were dealt with very well and quickly.”

 Bonus: Vaporizers from Dr. Dabber come with a 1- or 2-year warranty depending on product. They also offer discounts to military, first responders, and teachers.

Filed Under: CBD Health

Alpha-Cat®

November 27, 2020 by CBD OIL

In addition to a solid product lineup, Alpha-Cat offers accessible testing kits for cannabidiol (CBD) and other cannabinoids

True price:  0.04€-0.17€ (~$0.05-$0.20)

Product selection: Testing kits, calibration charts, e-liquids, concentrates, tincture oils, body cream, capsules, and isolate

Isolates or full spectrum: Isolates and broad spectrum

Dosage range: 100 to 6,000 mg

Pet products: No

29.00€ from Alpha-Cat

The Good
Unique testing kits • Quality standards • International shipping • Organic & vegan

The Bad
Lab tests not published • Kits may require training

The Bottom Line
If you need to test product potency or just want to enjoy European CBD, Alpha-Cat is worth checking out

Who they are:  Alpha-Cat was founded by French cannabis scientist Sébastien Béguerie with a big goal: to “introduce a high-quality system for better production and usage of medical cannabis.”

It sounds lofty but Alpha-Cat takes strides with its affordable test kits for analyzing cannabinoids. At an international conference in 2013, Sébastien presented research backing up the reliability of the company’s tools. They now offer product training (and their own certification) in cannabis/hemp testing.

And if that weren’t enough, Alpha-Cat also produces high-grade CBD and cannabigerol (CBG) products. The hemp is registered with the European Union and “guaranteed to be free of pesticides, heavy metals, and other pollutants.” Although the labels bear “lab tested quality,” certificates of analysis are not published on the site.

Why they’re unique: Alpha-Cat’s claim to fame is their low-cost mobile test kit designed to bring cannabinoid testing to the masses. According to the site, costs add up to about 9 € (~$10.50) per sample–quite a stretch from the usual 100€–200€. Kit users include patients, scientists, developers, and even legendary cultivator/educator, Jorge Cervantes.

What products they have: Cannabinoid test kits and calibration charts, CBD concentrate paste, e-liquids, tinctures, ointment, capsules, and CBD isolate crystal. The tinctures are available with CBD, CBG, or a combination of the two. In each case, the cannabinoids are swimming in extra virgin olive oil from Provence, France. Mmm…

The concentrate paste dishes out up to 2,500 mg CBD from a medical-grade dispenser. E-liquids mingle 100-1,000 mg CBD isolate with a terpene blend that mimics the flavorful chemovar Jack Herer. But alas, time is of the essence, and the test kits deserve some attention.

The Alpha-Cat MINI kit affords 2-8 tests. The process works using a technique called thin-layer chromatography. The practical result is that the test turns certain colors depending on the cannabinoids present. The colors can then be matched to calibration charts. With a little math, it works for low and high potency products.

The MINI kit includes a calibration chart for CBD and THC. But Alpha-Cat also vends charts for CBG, cannabichromene (CBC), tetrahydrocannabivarin (THCV), and cannabinol (CBN).

For 10-40 tests, upgrade to the REGULAR kit. Supplies can be replenished with a refill pack worth another 20 tests. If this doesn’t cut it, you have the option of the Mobile Lab. This is an option geared toward professional use–it even comes with 16 hours of online training.

Bonus: The company’s research team is open to supporting cannabinoid research. Drop them a line!

The post Alpha-Cat® appeared first on CBD Health and Wellness.

Filed Under: CBD Health

  • « Go to Previous Page
  • Go to page 1
  • Interim pages omitted …
  • Go to page 106
  • Go to page 107
  • Go to page 108
  • Go to page 109
  • Go to page 110
  • Interim pages omitted …
  • Go to page 116
  • Go to Next Page »

Footer

  • Home
  • Privacy Policy
  • Terms of Service